Evidence map›Paper›PMID 39297332›Full record

ArticleSubstance use & addiction journal2025

Adverse Events at 1 Month Following Medication Initiation for Opioid Use Disorder Among Adolescents and Young Adults.

Mishka Terplan, Kevin E O'Grady, Laura B Monico, Robert P Schwartz, Jan Gryczynski, Marc J Fishman, Shannon Gwin Mitchell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Substance use & addiction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mishka TerplanFriends Research Institute, Baltimore, MD, USA.ORCID 0000-0002-2489-2942
Kevin E O'GradyDepartment of Psychology, University of Maryland, College Park, College Park, MD, USA.
Laura B MonicoFriends Research Institute, Baltimore, MD, USA.
Robert P SchwartzFriends Research Institute, Baltimore, MD, USA.
Jan GryczynskiFriends Research Institute, Baltimore, MD, USA.
Marc J FishmanMountain Manor Treatment Center, Baltimore, MD, USA.
Shannon Gwin MitchellFriends Research Institute, Baltimore, MD, USA.

Funding

Health Services Research: Extended Release Naltrexone for Opioid-Dependent YouthR01DA033391 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI MITCHELL, SHANNON GWIN · 2013 to 2018
$3.3M
NIDA NIH HHS R01 DA033391
6 · The paper itself

Abstract

backgroundWe assess adverse events (AEs) following medication initiation for adolescents and young adults with opioid use disorder (OUD).

methodsThis is a secondary analysis of a clinical trial of long-acting injectable naltrexone (LAI-naltrexone) among youth with OUD aged 15 to 21 years. Participants were recruited from residential treatment and placed into 1 of 3 treatment groups based on medication receipt at time of discharge (no medication, sublingual buprenorphine-naloxone [buprenorphine], or LAI-naltrexone). Frequencies and percentages of AEs by body system were compared by medication group at the 1-month follow-up visit. Logistic regression was used to compare groups on their likelihood of reporting an AE, overall and excluding injection site reactions.

resultsOf 199 participants, 71 (36%) received no medication, 59 (30%) buprenorphine, and 69 (35%) LAI-naltrexone at discharge. Participants who received LAI-naltrexone experienced more AEs, primarily due to injection site reactions (62%, accounting for 43% of all AEs among participants who received LAI-naltrexone). There were 6 reports of nonlethal overdose, 5 in the no medication, 1 in the buprenorphine, and none in the LAI-naltrexone group. Participants receiving LAI-naltrexone were more likely to report an AE compared to the other groups (

conclusionsExcluding injection site reactions, there were no significant differences in the likelihood of reporting an AE 1 month after receiving LAI-NTX, buprenorphine, and no medications. LAI-naltrexone should be among the medications offered for the treatment of OUD in youth.

Indexed as

BuprenorphineNaltrexoneNarcotic AntagonistsOpioid-Related DisordersAdolescentBuprenorphine, Naloxone Drug CombinationDelayed-Action PreparationsFemaleHumansMaleNaloxoneOpiate Substitution TreatmentYoung AdultBuprenorphineBuprenorphine, Naloxone Drug CombinationDelayed-Action PreparationsNaloxoneNaltrexoneNarcotic Antagonistsadolescentsadverse eventsbuprenorphinelong-acting injectable naltrexonemedicationopioid use disorderyoung adultsyouth

Identifiers

PMID39297332
PMCPMC13386349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.